Preclinical results indicate that anti-CD19 CAR-T cells are effective in depleting CD19+ B cells in a lupus model, eliminating autoantibody production, reversing disease manifestation in target organs, and increasing lifespan, suggesting long-term efficacy of this therapeutic approach (24, 25). Here, CD19 is linked to systemic lupus erythematosus.